Arbitrage SBIR Phase I to Phase II Funding Gap via Convertible Debt Bridge
- Organization
- National Science Foundation (NSF) / AICONIC BIOSCIENCES LLC
- Sector
- Early-stage biotech companies with SBIR Phase I funding facing Phase II funding gaps
- Location
- Location unspecified
Source reference
Executive summary
Current state
A biotech startup received $305,000 SBIR Phase I funding to develop an AI platform for compact gene therapy constructs targeting inherited hearing loss, with $350M revenue projections but significant commercial execution gaps between research validation and market adoption.
Market catalyst
SBIR Phase I provides only $305,000 over 18 months with expiration 12/31/2027, creating a predictable capital crunch where AICONIC must secure Phase II funding but faces 6-9 month application lag, leaving them vulnerable to bridge financing on unfavorable terms.
This report is synthesized intelligence, not verified instruction. Always confirm against the primary source before acting. Review the full legal disclaimer before proceeding.
Field notes
Intelligence ledger
Add new evidence, corrections, or practical context to this directive. Keep claims attributable to a source where possible.
Sign in to add intelligence or vote on a field note.
Field intel logs: [ 0 ] entries. No operative updates submitted for this directive. Submit intel to claim clearance.